2015 has been a stellar year for WuXi Healthcare Ventures. The venture capital firm with operations in the U.S. and China, has successfully raised millions of dollars for Tunitas Therapeutics, Ivenix, Inc, Beigene, Adagene Inc. and Juno Therapeutics, while around the same time closing a new fund with $290 million, exceeding its initial target of $200 million.
In a chat between The Biotechnician, Wei Li, PhD, founding partner of WuXi Healthcare Ventures, said that the success of the fund has been do to its ability to stay focused on its mission; to find, seed, and develop life science and healthcare businesses that can benefit the most from the firm's operational expertise, strategic support, capital, and the patience of a long-term perspective from the United States and China.
The strategy of WuXi Healthcare Ventures isn’t as complex as it may seem: find early-stage healthcare and biotechnology firms that are promising and have revolutionary therapies and drugs that can change the playing field. With years of experience of its leaders, finding these opportunities looks simpler than what it really is.
Maintaining a strong team is also one of WuXi Healthcare Ventures main traits and recipes for success. All of the firm’s founding and current partners have extensive experience in biotechnology, and have extensive experience working between the U.S. and China.
Even after recently launching a new fund and finding success with it, the firm just recently announced it has raised $30 million in series C financing for AltheaDx, Inc, a personalized medicine company. With 2015 being an interesting a strong year for WuXi Healthcare Ventures, 2016 should be possibly an even more interesting year with stronger markets coming from the U.S., China and Europe.